Compare Sea Limited (SE) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sea Limited vs Smith & Nephew plc — how do they compare? Sea Limited trades at $107.87 (market cap $69.41B), while Smith & Nephew plc trades at $27.67 (market cap $11.63B). The key difference: Sea Limited is far larger — about 6× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.85% dividend while Sea Limited pays none. Which is the better fit depends on your goals.
| SE | SNN | |
|---|---|---|
Market Cap | $69.41B | $11.63B |
Sector | Media | Health |
52-Week High | $196.50 | $38.53 |
52-Week Low | $78.16 | $27.80 |
Enterprise Value | $64.44B | $14.66B |
Dividend Yield | — | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sea Limited (SE) trades at $113.33, up 1.11% with bullish technical signals and strong analyst support. The company shows robust revenue growth from $16.8B in 2024 to $22.9B in 2025, with net income reaching $1.58B. Recent earnings beat expectations in Q1 and Q2 2026, while operating cash flow improved significantly to $5.02B in 2025. Technical indicators show bullish moving averages with support at $111 and resistance at $115.
SE presents a compelling growth story with expanding profitability and positive cash flow generation. However, elevated valuation multiples (P/E 43.76) and insider selling activity warrant caution. The consensus price target of $143.67 suggests 27% upside potential, but investors should monitor competitive pressures in Southeast Asian markets and execution risks as the company scales.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sea Limited
Sea Limited offers information technology services. The Company provides online personal computer and mobile digital content, e-commerce, and payment platforms. Sea serves customers worldwide.
Read more on SE →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
